Probabilistic cost-minimisation analysis of darbepoetin alpha

Document downloaded from http://www.elsevier.es, day 26/02/2010. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.

Farm Hosp. 2009;33(4):208-216

Farmacia HOSPITALARIA
www.elsevier.es/farmhosp
• •

Farmacia HOSPITALARIA
Editorial
181 Controversias sobre medicamentos biosimilares y su intercambio terapéutico B. DorantesCalderón

Volumen 33. Número 4. Julio-Agosto 2009

ÓRGANO OFICIAL DE EXPRESIÓN CIENTÍFICA DE LA SOCIEDAD ESPAÑOLA DE FARMACIA HOSPITALARIA

Revisión
183 Síndrome de realimentación M.T. Fernández López, M.J. López Otero, P. Álvarez Vázquez, J. Arias Delgado y J.J. Varela Correa

Originales
194 Predicción de riesgo de rechazo agudo en pacientes con trasplante renal M.A. López-Montenegro Soria,B. Porta Oltra, N.V. Jiménez Torres y L. Pallardó Mateu 202 Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial C. Vicente, N. Serrano, M.J. Agustín, V. Alonso, P. Palomo y R. Huarte 208 Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la prácticaclínica española A. Sanz-Granda 217 Gestión de la devolución de tratamientos antineoplásicos y de su reutilización en pacientes oncológicos D. Yuste-Vila, A. Albert-Mari, V. Jiménez-Arenas y V.N. Jiménez-Torres

Original breve
224 Mortalidad en pacientes con demencia tratados con antipsicóticos atípicos (olanzapina, quetiapina y ziprasidona) L. Martínez Martínez, M.R. Olivera Fernández y G.Piñeiro Corrales

Cartas al Director
229 Necrólisis epidérmica tóxica (enfermedad de Lyell) secundaria a alopurinol L. Cid Conde, E. Novoa Fernández y B. Padrón Rodríguez 230 Disfagia neuromuscular asociada a risperidona B. Montañés-Pauls y D. Moya-Ripolles 231 Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso M. Gutiérrez García, E. López Lunar, O. Fernández Arenas, F.J.Hidalgo Correas y B. García Díaz

www.elsevier.es/farmhosp

ORIGINAL ARTICLE

Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice
A. Sanz-Granda
Especialista en Farmacia Hospitalaria, Proyectos de Farmacoeconomía, Navacerrada (Madrid), Spain Received December 5, 2008;accepted April 21, 2009

KEYWORDS Darbepoetin alpha; Epoetin alpha; Anaemia; Chronic renal failure; Cost minimisation; Probabilistic model

Abstract Introduction: The direct transfer of the results of pharmaco-economic studies between countries may not be suitable if the proper adaptations are not made to take into account differences in treatment patterns, resource use, and costs fromcountry to country. Objective: To estimate the cost in Spain of treating anaemia secondary to chronic renal failure with darbepoetin alpha or epoetin alpha from a review and analysis of available current information. In addition, the role of the route of administration as a main driver of the cost will be analysed. Method: Population: patients with chronic renal failure induced anaemia. Data: Medlineand Embase search of studies directly comparing erythropoiesis stimulating agents. Analysis: Cost minimization analysis from the perspective of a hospital pharmacy department. The main outcome chosen was the difference between the average cost per patient undergoing a 30-day treatment with epoetin alpha versus darbepoetin alpha. Results: a) Haemodialysis: changing from epoetin alpha to darbepoetinalpha is associated with a cost reduction of 8.67%; 95% CI, —1.34 to 17.92 (€uro17.48; 95% CI, —2.70 to 36.13); probabilistic analysis showed that the use of darbepoetin alpha could be associated with a costsaving probability of 94.9%. The IV administration yielded a decrease in costs of about 16.00%; 95% CI, —2.38 to 36.77 (€uro41.78, 95% CI: —6.21 to 96.04); b) Pre-dialysis: darbepoetin alpha...